Corticotropin-releasing factor 1 receptor antagonists: A patent review

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 8, 2013, Pages 1057-1068

  Williams, John P ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

Adrenocorticotropic hormone; Corticotropin releasing factor; CRF1 antagonist; Stress

Indexed keywords

2 THIENYL; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 5 THIAZOLYL; 5,5 BICYCLIC IMIDAZO[4,5 C]PYRAZOLE; 5,5 BICYCLIC PYRAZOLO[3,2 B ][1,3]OXAZOLE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CP 316 311; CP 3160311; HORMONE RECEPTOR BLOCKING AGENT; IMIDAZO[1,2 B]PYRIDAZINE; IMIDAZOPYRIDINE DERIVATIVE; NBI 34041; PEXACERFONT; PYRAZOLE DERIVATIVE; PYRAZOLO[3,2 B][1,3]THIAZOLE; PYRAZOLONE; PYRAZOLOPYRIMIDINE DERIVATIVE; SR 125543; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VERUCERFONT;

ANXIETY DISORDER; BINDING AFFINITY; CLINICAL EVALUATION; DEPRESSION; DRUG EFFICACY; DRUG TREATMENT FAILURE; ELECTRON; HUMAN; HYDROGEN BOND; IC 50; LIPOPHILICITY; MAJOR DEPRESSION; MOLECULAR WEIGHT; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; RECEPTOR OCCUPANCY; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY;

ALLOSTERIC REGULATION; ANIMALS; ANXIETY; DEPRESSION; DRUG DESIGN; HUMANS; PATENTS AS TOPIC; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRESS, PSYCHOLOGICAL;

EID: 84880684989     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.795545     Document Type: Review

References (77)

1. Vale WW, Spiess J, Rivier C, Rivier J Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin Science 1981;213:1394-7
2. Chen R, Lewis KA, Perrin MH, Vale WW Expression cloning of a human corticotropin-releasing factor receptor Proc Natl Acad Sci USA 1993;90:8967-71
3. Lovenberg TW, Liaw CW, Grigoriadis DE, et al Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain Proc Natl Acad Sci USA 1995;92:836-40
4. Donaldson C J, Sutton SW, Perrin MH, et al Cloning and characterization of human urocortin Endrocrinology 1996;137:2167-70
5. Reyes TM, Lewis K, Perrin MH, et al Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors Proc Natl Acad Sci USA 2001;98:2843-8
6. Lewis K, Perrin MH, Blount A, et al Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor Proc Natl Acad Sci USA 2001;98:7570-5
7. Zorrilla EP, Koob GF Progress in corticotropin-releasing factor-1 antagonist development Drug Discov Today 2010;15:371-83
8. Gilligan PJ Corticotropin-releasing factor receptor antagonists Expert Opin Ther Patents 2006;16:913-24
9. Dzierba CD, Hartz RA, Bronson JJ Recent advances in corticotropin- releasing factor receptor antagonists Annu Rep Med Chem 2008;43:3-19
10. Nova Pharmaceutical Corp Corticotropin-releasing factor antagonism compounds US5063245; 1991
11. Zobel AW, Nickel T, Kunzel HE, et al Effects of the high-affinity corticotropinreleasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated J Psychiatr Res 2000;34:171-81
12. Ising M, Zimmerman US, Kunzel HE, et al High-affinity CRF (1) receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response Neuropsychopharmacology 2007;32:1941-9
13. Binneman B, Feltner D, Kolluri S, et al A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment ofmajor depression Am J Pyschiatry 2008;165:617-20
14. Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder Neurocrine Biosciences press release 2010 Available from: www.neurocrine com [Last accessed 22 February 2013]
15. Coric V, Feldman HH, Oren DA, et al Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder Depress Anxiety 2010;27:417-25
16. Evaluation of GSK561679 in Women with Post-Traumatic Stress Disorder Clincaltrials.gov identifier NCT01018992 Available from: clinicaltrials.gov [Last accessed 22 February 2013]
17. Effects of Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism on Stress-Induced Craving in Alcoholic Women with High Anxiety Clincaltrials.gov identifier NCT01187511 Available from: clinicaltrials.gov [Last accessed 22 February 2013]
18. Pexacerfont for Stress-induced Food Craving Clincaltrials.gov identifier NCT01656577 Available from: clinicaltrials.gov [Last accessed 22 February 2013]
19. Pexacerfont to Reduce Stress-induced Tobacco Craving Clinicaltrials.gov identifier NCT01557556 Available from: clinicaltrials.gov [Last accessed 22 February 2013]
20. Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics Clinicaltrials.gov identifier NCT01227980 Available from: clinicaltrials.gov [Last accessed 22 February 2013]
21. Keller PA, Bowman M, Dang KH, et al Pharmacophore development for corticotropin-releasing hormone: new insights into inhibitor activity J Med Chem 1999;42:2351-7
22. Gross RS, Guo Z, Dyck B, et al Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists J Med Chem 2005;48:5780-93
23. Taisho Pharmaceutical Co 8-Aryl-4-alkylpyrollo[2,3,4-de]quinolin-5(4H)- one and 8-aryl-4-alkyl-4,5-dihydropyrrolo [2,3,4-de]quinolin-5-ol derivatives WO2009008552; 2009
24. Pfizer Ltd Substituted 6,6-heterobicyclic derivatives WO9808846; 1998
25. Emory University Compounds, compositions, methods of synthesis, and methods of treatment WO2010096426; 2010
26. Pfizer Ltd Preparation of substituted purine compounds as CRF1 receptor antagonists WO2009144632; 2009
27. Miller DC, Klute W, Brown AD Discovery of potent, metabolically stable purine CRF-1 antagonists with differentiated binding kinetic profiles Bioorg Med Chem Lett 2011;21:6108-11
28. Fleck BA, Hoare SRJ, Pick RR, et al Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor J Pharmacol Exp Ther 2012;341:518-31
29. Eli Lilly and Co Thiazolylpyrazolopyrimidines as CRF1 receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of diseases WO2008036579; 2008
30. Eli Lilly and Co Preparation of thiophene pyrazolopyrimidine compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists WO2008036541; 2008
31. SB Pharmaco Puerto Rico, Inc Neurocrine Biosciences, Inc CRF receptor antagonists and methods relating thereto WO2006044821; 2006
32. Eli Lilly and Co Imidazopyridazine compounds WO2006102194; 2006
33. Eli Lilly and Co Imidazopyridazine compounds WO2006107784; 2006
34. Gehlert DR, Cippitelli A, Thorsell A, et al 3-(4-Chloro-2-morpholin-4- ylthiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridizine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism J Neurosci 2007;27:2718-26
35. Du Pont Pharmaceuticals Co Nitrogen substituted imidazo[4,5-c]pyrazoles as corticotropin releasing hormone antagonists WO9910350; 1999
36. Eisai R&D Management Co Pyrazoloxazole compound WO2011043387; 2011
37. Novartis AG Pyrazolo[5,1-b]oxazole derivatives as CRF1 antagonists WO2010015628; 2010
38. Novartis AG Pyrazolo[5,1-b]oxazole derivatives as CRF-1 receptor antagonists WO2011092290; 2011
39. Eisai R&D Management Co Pyrazolothiazole compound WO2011043381; 2011
40. Eisai R&D Management Co 3-Phenylpyrazolo[5,1-b]thiazole compounds US20090259049; 2009
41. Takahashi Y, Hashizume M, Shin K, et al Design, synthesis, and structure-activity relationships of novel pyrazolo[5,1-b]thiazole derivatives as potent and orally active corticotropin-releasing factor 1 receptor antagonists J Med Chem 2012;55:8450-63
42. Bristol-Myers Squibb Co Pyrazinone modulator of corticotropin-releasing factor receptor activity WO2010014280; 2010
43. Du Pont Merck Pharmaceutical Co Pyrazinones and triazinones and their derivatives thereof WO9811075; 1998
44. Hartz RA, Ahuja VT, Zhuo X, et al A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6- (difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2- carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist J Med Chem 2009;52:7653-68
45. Bristol-Myers Squibb Co Substituted carbamate derivatives as modulators of corticotropin-releasing factor receptor activity WO2010014687; 2010
46. Whitten JP, Xie YF, Erickson PE, et al Rapid microscale synthesis, a new method for lead optimization using robotics and solution phase chemistry: application to the synthesis and optimization of corticotropin-releasingfactor1 receptor antagonists J Med Chem 1996;39:4354-7
47. Saito T, Obitsu T, Kondo T, et al 6-7-Dihydro-5H-cyclopenta[d]pyrazolo[1, 5-A] pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists Bioorg Med Chem 2011;19:5432-45
48. Saito T, Obitsu T, Minamoto C, et al Pyrazolo[1,5-A]pyrimidines, triazolo[1,5-A]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF1) receptor antagonists Bioorg Med Chem 2011;19:5955-66
49. Tanabe Seiyaku Co Pyrazolopyrimidine derivative WO2006126718; 2006
50. Takeda Pharmaceutical Co Ltd Tricyclic compounds and use thereof US20090186879; 2009
51. Takeda Pharmaceutical Co Ltd Fused heterocyclic compounds WO2006116412; 2006
52. Takeda K, Terauchi T, Shin K, et al Design, synthesis and structure-activity relationships of 5-alkylaminolquinolines as a novel series of CRF1 receptor antagonists Bioorg Med Chem Lett 2012;22:4756-61
53. Takeda Pharmaceutical Co Ltd Benzimidazole compounds WO2008051533; 2008
54. Takeda Pharmaceutical Co Ltd Fused heterocyclic compounds having CRF antagonistic activity WO2008082003; 2008
55. Elf Sanofi Branched alkylamino derivatives of thiazole, processes for preparing them and pharmaceutical compositions containing them US5464847; 1995
56. A trial evaluating the efficacy and tolerability of SSR125543 in outpatients with major depressive disorder (AGATE) Clincaltrials.gov identifier NCT01034995 Available from: clinicaltrials.gov [Last accessed 22 February 2013]
57. Yoon T, De Lombaert S, Brodbeck R, et al 2-Arylpyrimidines: novel CRF1 receptor antagonists Bioorg Med Chem Lett 2008;18:4486-90
58. Ono Pharmaceutical Co Bicyclic heterocyclic compound WO2007069565; 2007
59. Ono Pharmaceutical Co Bicyclic heterocyclic compound WO2007069671; 2007
60. Ono Pharmaceutical Co Bicyclic heterocyclic compound WO2008136377; 2008
61. Takeda K, Teruachi T, Hashizume M, et al Design, synthesis and structure-activity relationships of a series of 2-Ar-8-methyl-5- alkylaminoquinolines as novel CRF1 receptor antagonists Bioorg Med Chem Lett 2012;22:5372-8
62. Neurogen Corp CRF1 Receptor ligands comprising fused bicyclic heteroaryl moieties WO2008083070; 2008
63. Saito T, Obitsu T, Kohno H, et al Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f] triazine-(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF1) receptor antagonists Bioorg Med Chem 2012;20:1122-38
64. Neurogen Corp N-Benzimidazolylmethyl-and N-indolylmethy-benzamides and their use as CRF modulators WO2000059888; 2000
65. Japan Tobacco Benzamide derivative and use thereof WO2001062718; 2001
66. Wilson DM, Termin AP, Mao L, et al Arylamidrazones as novel corticotropin releasing factor receptor antagonists J Med Chem 2002;45:2123-6
67. Molteni V, Penzotti J, Wilson DM, et al N-Phenylphenylglycines as novel corticotropin releasing factor receptor antagonists J Med Chem 2004;47:2426-9
68. Saito K, Kasai T, Nagura Y, et al Corticotropin-releasing hormone receptor 1 antagonist blocks brain-gut activation induced by colonic distension in rats Gastroenterology 2005;129:1533-43
69. Novartis AG Cyclohexyl amide derivatives and their use as CRF-1 receptor antagonists WO2010015655; 2010
70. Novartis AG Cyclohexyl amide derivatives as CRF receptor antagonists WO2011092293; 2011
71. Novartis AG Cyclohexyl amide derivatives as CRF receptor antagonists WO2011095450; 2011
72. Paez-Pareda M, Hausch F, Holsboer F Corticotropin releasing factor receptor antagonists for major depressive disorder Expert Opin Investig Drugs 2011;20:519-35
73. Koob G, Zorrilla EP Update on corticotropin-releasing factor pharmacotherapy for psychiatric disorders: a revisionist view Neuropsychopharmacology 2012;37:308-9
74. Hoare SRJ Mechanisms of peptide and nonpeptide ligand binding to class B G-protein-coupled receptors Drug Discov Today 2005;10:417-27
75. Bale TL, Contarino A, Smith GW, et al Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress Nat Genet 2000;24:410-14
76. Preil J, Muller MB, Gesing A, et al Regulation of the hypothalamic-pituitary-adrenocortical system in mice deficient for CRH receptors 1 and2 Endocrinology 2001;142:4946-55
77. Chandler DJ Something's got to give: psychiatric disease on the rise and novel drug development on the decline Drug Discov Today 2013;18:202-6